This study investigates the use of medical cannabis in patients with advanced pancreatic and colorectal cancer. The purpose of this study is to explore how medical cannabis can impact the symptom burden experienced by these patients.

The study evaluates the effectiveness of medical cannabis in managing symptoms such as nausea, vomiting, anorexia, cachexia, and pain. It focuses on understanding the potential benefits of cannabis in improving the quality of life for patients with these conditions.

• Who can participate: Adults aged 18 or older with advanced pancreatic or colorectal cancer can participate. Participants must reside in Minnesota, be willing to join the Minnesota Medical Cannabis Program, and must not have used THC products regularly in the last month.
• Study details: Participants will be assigned to receive medical cannabis either immediately or after a delay. The study will assess symptom relief and safety of cannabis use. A placebo is not used in this study. Participants must adhere to the Minnesota Medical Cannabis Program.
• Study timelines: The study will last 16 weeks.